Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2016: 1.000
Source Normalized Impact per Paper (SNIP) 2016: 1.112

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 51, Issue 3 (Mar 2013)

Issues

Molecular mechanisms underlying the potentially adverse effects of folate

Kyle C. Strickland
  • Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC, USA
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Natalia I. Krupenko
  • Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC, USA
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Sergey A. Krupenko
  • Corresponding author
  • Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC, USA
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2012-12-12 | DOI: https://doi.org/10.1515/cclm-2012-0561

Abstract

The importance of proper consumption of dietary folate for human health has been highlighted by an extensive number of publications over several decades. Fortification of grain products with folic acid was initiated with the specific intent to prevent neural tube defects, and the scope of this endeavor is unique in that its target population (women of the periconceptional period) is many times smaller than the population it affects (everyone who ingests fortified grain products). Folate fortification has been wildly successful in terms of its goal; since its inception, the incidence of neural tube defects has markedly decreased. In the wake of this public health triumph, it is important to catalog both the serendipitous benefits and potential side effects of folic acid supplementation. The vitamin is generally regarded as a harmless nutrient based on studies evaluating the safe upper limits of folate intake. In recent years, however, a concern has been raised with respect to a potential downside to folate supplementation; namely, its proposed ability to enhance proliferation of malignant tumors. The current review summarizes the available literature on the effects of folate supplementation and the molecular mechanisms by which high doses of folate may have negative consequences on human health, especially with regard to cancer.

Keywords: cancer; dietary supplementation; folate; folate enzymes; folic acid; metastasis; molecular mechanisms

References

  • 1.

    Stover PJ. Physiology of folate and vitamin B12 in health and disease. Nutr Rev 2004;62:S3–12; discussion S3.CrossrefGoogle Scholar

  • 2.

    Benedek TG. Methotrexate: from its introduction to non-oncologic therapeutics to anti-TNF-alpha. Clin Exp Rheumatol 2010;28:S3–8.Google Scholar

  • 3.

    Herrmann W, Obeid R. The mandatory fortification of staple foods with folic acid: a current controversy in Germany. Dtsch Arztebl Int 2011;108:249–54.Google Scholar

  • 4.

    Obeid R, Herrmann W. The emerging role of unmetabolized folic acid in human diseases: myth or reality? Curr Drug Metab 2012 Jun 29. [Epub ahead of print].CrossrefGoogle Scholar

  • 5.

    CDC Grand Rounds: additional opportunities to prevent neural tube defects with folic acid fortification. MMWR Morb Mortal Wkly Rep 2010;59:980–4.Google Scholar

  • 6.

    Bukowski R, Malone FD, Porter FT, Nyberg DA, Comstock CH, Hankins GD, et al. Preconceptional folate supplementation and the risk of spontaneous preterm birth: a cohort study. PLoS Med 2009;6:e1000061.CrossrefGoogle Scholar

  • 7.

    Carr DF, Whiteley G, Alfirevic A, Pirmohamed M. Investigation of inter-individual variability of the one-carbon folate pathway: a bioinformatic and genetic review. Pharmacogenomics J 2009;9:291–305.PubMedCrossrefGoogle Scholar

  • 8.

    Bailey SW, Ayling JE. The extremely slow and variable activity of dihydrofolate reductase in human liver and its implications for high folic acid intake. Proc Natl Acad Sci USA 2009;106:15424–9.CrossrefGoogle Scholar

  • 9.

    Suh JR, Herbig AK, Stover PJ. New perspectives on folate catabolism. Annu Rev Nutr 2001;21:255–82.CrossrefGoogle Scholar

  • 10.

    Sanderson P, McNulty H, Mastroiacovo P, McDowell IF, Melse-Boonstra A, Finglas PM, et al. Folate bioavailability: UK Food Standards Agency workshop report. Br J Nutr 2003;90:473–9.CrossrefGoogle Scholar

  • 11.

    Morris MS, Jacques PF, Rosenberg IH, Selhub J. Circulating unmetabolized folic acid and 5-methyltetrahydrofolate in relation to anemia, macrocytosis, and cognitive test performance in American seniors. Am J Clin Nutr 2010;91:1733–44.CrossrefGoogle Scholar

  • 12.

    Bailey RL, Mills JL, Yetley EA, Gahche JJ, Pfeiffer CM, Dwyer JT, et al. Unmetabolized serum folic acid and its relation to folic acid intake from diet and supplements in a nationally representative sample of adults aged > or =60 y in the United States. Am J Clin Nutr 2010;92:383–9.CrossrefGoogle Scholar

  • 13.

    Obeid R, Kasoha M, Kirsch SH, Munz W, Herrmann W. Concentrations of unmetabolized folic acid and primary folate forms in pregnant women at delivery and in umbilical cord blood. Am J Clin Nutr 2010;92:1416–22.CrossrefGoogle Scholar

  • 14.

    Obeid R, Kirsch SH, Kasoha M, Eckert R, Herrmann W. Concentrations of unmetabolized folic acid and primary folate forms in plasma after folic acid treatment in older adults. Metab Clin Exp 2011;60:673–80.Google Scholar

  • 15.

    Boilson A, Staines A, Kelleher CC, Daly L, Shirley I, Shrivastava A, et al. Unmetabolized folic acid prevalence is widespread in the older Irish population despite the lack of a mandatory fortification program. Am J Clin Nutr 2012;96:613–21.CrossrefGoogle Scholar

  • 16.

    Smith AD, Kim YI, Refsum H. Is folic acid good for everyone? Am J Clin Nutr 2008;87:517–33.Google Scholar

  • 17.

    Mason JB. Unraveling the complex relationship between folate and cancer risk. Biofactors 2011;37:253–60.CrossrefGoogle Scholar

  • 18.

    Ulrich CM, Potter JD. Folate and cancer – timing is everything. J Am Med Assoc 2007;297:2408–9.Google Scholar

  • 19.

    Lucock M, Yates Z. Folic acid fortification: a double-edged sword. Curr Opin Clin Nutr Metab Care 2009;12:555–64.CrossrefGoogle Scholar

  • 20.

    Elmore CL, Wu X, Leclerc D, Watson ED, Bottiglieri T, Krupenko NI, et al. Metabolic derangement of methionine and folate metabolism in mice deficient in methionine synthase reductase. Mol Genet Metab 2007;91:85–97.CrossrefGoogle Scholar

  • 21.

    Sittig LJ, Herzing LB, Xie H, Batra KK, Shukla PK, Redei EE. Excess folate during adolescence suppresses thyroid function with permanent deficits in motivation and spatial memory. Genes Brain Behav 2012;11:193–200.CrossrefGoogle Scholar

  • 22.

    Morris MC, Evans DA, Bienias JL, Tangney CC, Hebert LE, Scherr PA, et al. Dietary folate and vitamin B12 intake and cognitive decline among community-dwelling older persons. Arch Neurol 2005;62:641–5.CrossrefGoogle Scholar

  • 23.

    Leeming RJ, Lucock M. Autism: is there a folate connection? J Inherit Metab Dis 2009;32:400–2.CrossrefGoogle Scholar

  • 24.

    Zhou YH, Tang JY, Wu MJ, Lu J, Wei X, Qin YY, et al. Effect of folic acid supplementation on cardiovascular outcomes: a systematic review and meta-analysis. PloS one 2011;6:e25142.CrossrefGoogle Scholar

  • 25.

    Clarke R, Halsey J, Bennett D, Lewington S. Homocysteine and vascular disease: review of published results of the homocysteine-lowering trials. J Inherit Metab Dis 2011;34:83–91.CrossrefGoogle Scholar

  • 26.

    Heseker HB, Mason JB, Selhub J, Rosenberg IH, Jacques PF. Not all cases of neural-tube defect can be prevented by increasing the intake of folic acid. Br J Nutr 2009;102:173–80.CrossrefGoogle Scholar

  • 27.

    Marean A, Graf A, Zhang Y, Niswander L. Folic acid supplementation can adversely affect murine neural tube closure and embryonic survival. Hum Mol Genet 2011;20:3678–83.CrossrefGoogle Scholar

  • 28.

    Butterworth CE Jr., Tamura T. Folic acid safety and toxicity: a brief review. Am J Clin Nutr 1989;50:353–8.Google Scholar

  • 29.

    Oleinik NV, Krupenko NI, Reuland SN, Krupenko SA. Leucovorin-induced resistance against FDH growth suppressor effects occurs through DHFR up-regulation. Biochem Pharmacol 2006;72:256–66.CrossrefGoogle Scholar

  • 30.

    Sauer J, Mason JB, Choi SW. Too much folate: a risk factor for cancer and cardiovascular disease? Curr Opin Clin Nutr Metab Care 2009;12:30–6.CrossrefGoogle Scholar

  • 31.

    Matthews RG, Daubner SC. Modulation of methylenetetrahydrofolate reductase activity by S-adenosylmethionine and by dihydrofolate and its polyglutamate analogues. Adv Enzyme Regul 1982;20:123–31.CrossrefGoogle Scholar

  • 32.

    Troen AM, Mitchell B, Sorensen B, Wener MH, Johnston A, Wood B, et al. Unmetabolized folic acid in plasma is associated with reduced natural killer cell cytotoxicity among postmenopausal women. J Nutr 2006;136:189–94.Google Scholar

  • 33.

    Hirsch S, Miranda D, Fuentes C, Leiva L, Barrera G, Montoya M, et al. Effect of supraphysiological concentration of serum folate on natural killer cell activity in healthy subjects. e-SPAN J 2012;7:e125–8.Google Scholar

  • 34.

    Farber S, Cutler EC, Hawkins JW, Harrison JH, Peirce EC 2nd, Lenz GG. The action of pteroylglutamic conjugates on man. Science 1947;106:619–21.CrossrefGoogle Scholar

  • 35.

    Choi SW, Mason JB. Folate and carcinogenesis: an integrated scheme. J Nutr 2000;130:129–32.Google Scholar

  • 36.

    Rock CL, Lampe JW, Patterson RE. Nutrition, genetics, and risks of cancer. Annu Rev Public Health 2000;21:47–64.CrossrefGoogle Scholar

  • 37.

    Mason JB. Folate status: effects on carcinogenesis. In: Bailey LB, editor. Folate in health and disease. New York: Marcel Dekker Inc., 1995:361–78.Google Scholar

  • 38.

    Goldman ID, Chattopadhyay S, Zhao R, Moran R. The antifolates: evolution, new agents in the clinic, and how targeting delivery via specific membrane transporters is driving the development of a next generation of folate analogs. Curr Opin Investig Drugs 2010;11:1409–23.Google Scholar

  • 39.

    Ly A, Lee H, Chen J, Sie KK, Renlund R, Medline A, et al. Effect of maternal and postweaning folic acid supplementation on mammary tumor risk in the offspring. Cancer Res 2011;71: 988–97.CrossrefGoogle Scholar

  • 40.

    McKay JA, Williams EA, Mathers JC. Gender-specific modulation of tumorigenesis by folic acid supply in the Apc mouse during early neonatal life. Br J Nutr 2008;99:550–8.Google Scholar

  • 41.

    Ebbing M, Bonaa KH, Nygard O, Arnesen E, Ueland PM, Nordrehaug JE, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B12. J Am Med Assoc 2009;302:2119–26.CrossrefGoogle Scholar

  • 42.

    Figueiredo JC, Grau MV, Haile RW, Sandler RS, Summers RW, Bresalier RS, et al. Folic acid and risk of prostate cancer: results from a randomized clinical trial. J Natl Cancer Inst 2009;101:432–5.CrossrefGoogle Scholar

  • 43.

    Larsson SC, Giovannucci E, Wolk A. Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis. Gastroenterology 2006;131:1271–83.CrossrefGoogle Scholar

  • 44.

    Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS, et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. J Am Med Assoc 2007;297:2351–9.Google Scholar

  • 45.

    Kim YI. Folic acid supplementation and cancer risk: point. Cancer Epidemiol Biomarkers Prev 2008;17:2220–5.CrossrefGoogle Scholar

  • 46.

    Kawakita D, Matsuo K, Sato F, Oze I, Hosono S, Ito H, et al. Association between dietary folate intake and clinical outcome in head and neck squamous cell carcinoma. Ann Oncol 2012;23:186–92.CrossrefGoogle Scholar

  • 47.

    Ibiebele TI, Hughes MC, Pandeya N, Zhao Z, Montgomery G, Hayward N, et al. High intake of folate from food sources is associated with reduced risk of esophageal cancer in an Australian population. J Nutr 2011;141:274–83.CrossrefGoogle Scholar

  • 48.

    Welzel TM, Katki HA, Sakoda LC, Evans AA, London WT, Chen G, et al. Blood folate levels and risk of liver damage and hepatocellular carcinoma in a prospective high-risk cohort. Cancer Epidemiol Biomarkers Prev 2007;16:1279–82.CrossrefGoogle Scholar

  • 49.

    French AE, Grant R, Weitzman S, Ray JG, Vermeulen MJ, Sung L, et al. Folic acid food fortification is associated with a decline in neuroblastoma. Clin Pharmacol Therapeut 2003;74:288–94.CrossrefGoogle Scholar

  • 50.

    Vargas AJ, Thompson PA. Diet and nutrient factors in colorectal cancer risk. Nutr Clin Pract 2012;27:613–23.CrossrefGoogle Scholar

  • 51.

    Kotsopoulos J, Kim YI, Narod SA. Folate and breast cancer: what about high-risk women? Cancer Causes Control 2012;23:1405–20.CrossrefGoogle Scholar

  • 52.

    Donkena KV, Karnes RJ, Young CY. Vitamins and prostate cancer risk. Molecules 2010;15:1762–83.CrossrefGoogle Scholar

  • 53.

    Roswall N. Folate and lung cancer risk. Lung Cancer 2010;67:380–1.CrossrefGoogle Scholar

  • 54.

    Ulrich CM. Folate and cancer prevention: a closer look at a complex picture. Am J Clin Nutr 2007;86:271–3.Google Scholar

  • 55.

    Ulrich CM, Neuhouser M, Liu AY, Boynton A, Gregory JF 3rd, Shane B, et al. Mathematical modeling of folate metabolism: predicted effects of genetic polymorphisms on mechanisms and biomarkers relevant to carcinogenesis. Cancer Epidemiol Biomarkers Prev 2008;17:1822–31.CrossrefGoogle Scholar

  • 56.

    Han SS, Sue LY, Berndt SI, Selhub J, Burdette LA, Rosenberg PS, et al. Associations between genes in the one-carbon metabolism pathway and advanced colorectal adenoma risk in individuals with low folate intake. Cancer Epidemiol Biomarkers Prev 2012;21:417–27.CrossrefGoogle Scholar

  • 57.

    Liu AY, Scherer D, Poole E, Potter JD, Curtin K, Makar K, et al. Gene-diet-interactions in folate-mediated one-carbon metabolism modify colon cancer risk. Mol Nutr Food Res 2012 Sep 7. [Epub ahead of print].Google Scholar

  • 58.

    Jhaveri MS, Wagner C, Trepel JB. Impact of extracellular folate levels on global gene expression. Mol Pharmacol 2001;60:1288–95.Google Scholar

  • 59.

    Blount BC, Mack MM, Wehr CM, MacGregor JT, Hiatt RA, Wang G, et al. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. Proc Natl Acad Sci USA 1997;94:3290–5.CrossrefGoogle Scholar

  • 60.

    Kruman II, Kumaravel TS, Lohani A, Pedersen WA, Cutler RG, Kruman Y, et al. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer’s disease. J Neurosci 2002;22:1752–62.Google Scholar

  • 61.

    Duthie SJ, Hawdon A. DNA instability (strand breakage, uracil misincorporation, and defective repair) is increased by folic acid depletion in human lymphocytes in vitro. FASEB J 1998;12:1491–7.Google Scholar

  • 62.

    Duthie SJ. Folic acid deficiency and cancer: mechanisms of DNA instability. Br Med Bull 1999;55:578–92.CrossrefGoogle Scholar

  • 63.

    Bistulfi G, Foster BA, Karasik E, Gillard B, Miecznikowski J, Dhiman VK, et al. Dietary folate deficiency blocks prostate cancer progression in the TRAMP model. Cancer Prev Res (Phila) 2011;4:1825–34.CrossrefGoogle Scholar

  • 64.

    Khanna D, Park GS, Paulus HE, Simpson KM, Elashoff D, Cohen SB, et al. Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies. Arthritis Rheum 2005;52:3030–8.CrossrefGoogle Scholar

  • 65.

    Carter JY, Loolpapit MP, Lema OE, Tome JL, Nagelkerke NJ, Watkins WM. Reduction of the efficacy of antifolate antimalarial therapy by folic acid supplementation. Am J Trop Med Hyg 2005;73:166–70.Google Scholar

  • 66.

    van Eijk AM, Ouma PO, Williamson J, Ter Kuile FO, Parise M, Otieno K, et al. Plasma folate level and high-dose folate supplementation predict sulfadoxine-pyrimethamine treatment failure in pregnant women in Western kenya who have uncomplicated malaria. J Infect Dis 2008; 198:1550–3.Google Scholar

  • 67.

    Salim A, Tan E, Ilchyshyn A, Berth-Jones J. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 2006;154:1169–74.CrossrefGoogle Scholar

  • 68.

    Greenhalgh J, McLeod C, Bagust A, Boland A, Fleeman N, Dundar Y, et al. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess 2010;14:33–9.Google Scholar

  • 69.

    Tisman G, Garcia A. Control of prostate cancer associated with withdrawal of a supplement containing folic acid, L-methyltetrahydrofolate and vitamin B12: a case report. J Med Case Reports 2011;5:413.CrossrefGoogle Scholar

  • 70.

    Crott JW, Choi SW, Ordovas JM, Ditelberg JS, Mason JB. Effects of dietary folate and aging on gene expression in the colonic mucosa of rats: implications for carcinogenesis. Carcinogenesis 2004;25:69–76.Google Scholar

  • 71.

    Crott JW, Liu Z, Keyes MK, Choi SW, Jang H, Moyer MP, et al. Moderate folate depletion modulates the expression of selected genes involved in cell cycle, intracellular signaling and folate uptake in human colonic epithelial cell lines. J Nutr Biochem 2008;19:328–35.CrossrefGoogle Scholar

  • 72.

    Lewis CM, Smith AK, Kamen BA. Receptor-mediated folate uptake is positively regulated by disruption of the actin cytoskeleton. Cancer Res 1998;58:2952–6.Google Scholar

  • 73.

    Oser M, Condeelis J. The cofilin activity cycle in lamellipodia and invadopodia. J Cell Biochem 2009;108:1252–62.CrossrefGoogle Scholar

  • 74.

    Bernstein BW, Bamburg JR. ADF/cofilin: a functional node in cell biology. Trends Cell Biol 2010;20:187–95.CrossrefGoogle Scholar

  • 75.

    Zhu H, Cabrera RM, Wlodarczyk BJ, Bozinov D, Wang D, Schwartz RJ, et al. Differentially expressed genes in embryonic cardiac tissues of mice lacking Folr1 gene activity. BMC Dev Biol 2007;7:128.Google Scholar

  • 76.

    Chanson A, Sayd T, Rock E, Chambon C, Sante-Lhoutellier V, Potier de Courcy G, et al. Proteomic analysis reveals changes in the liver protein pattern of rats exposed to dietary folate deficiency. J Nutr 2005;135:2524–9.Google Scholar

  • 77.

    Oleinik NV, Krupenko NI, Krupenko SA. ALDH1L1 inhibits cell motility via dephosphorylation of cofilin by PP1 and PP2A. Oncogene 2010;29:6233–44.CrossrefGoogle Scholar

  • 78.

    Winter-Vann AM, Kamen BA, Bergo MO, Young SG, Melnyk S, James SJ, et al. Targeting Ras signaling through inhibition of carboxyl methylation: an unexpected property of methotrexate. Proc Natl Acad Sci USA 2003;100:6529–34.CrossrefGoogle Scholar

  • 79.

    Bjorklund NK, Gordon R. A hypothesis linking low folate intake to neural tube defects due to failure of post-translation methylations of the cytoskeleton. Int J Dev Biol 2006;50:135–41.CrossrefGoogle Scholar

  • 80.

    Gao Y, Sztul E. A novel interaction of the Golgi complex with the vimentin intermediate filament cytoskeleton. J Cell Biol 2001;152:877–94.CrossrefGoogle Scholar

  • 81.

    Gao YS, Vrielink A, MacKenzie R, Sztul E. A novel type of regulation of the vimentin intermediate filament cytoskeleton by a Golgi protein. Eur J Cell Biol 2002;81:391–401.PubMedCrossrefGoogle Scholar

  • 82.

    Fox JT, Stover PJ. Folate-mediated one-carbon metabolism. Vitam Horm 2008;79:1–44.Google Scholar

  • 83.

    Tibbetts AS, Appling DR. Compartmentalization of Mammalian folate-mediated one-carbon metabolism. Ann Rev Nutr 2010;30:57–81.CrossrefGoogle Scholar

  • 84.

    Kelemen LE. The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer 2006;119:243–50.CrossrefGoogle Scholar

  • 85.

    Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R, Bertino JR. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta 2002;1587:164–73.Google Scholar

  • 86.

    Gao L, Chalupsky K, Stefani E, Cai H. Mechanistic insights into folic acid-dependent vascular protection: dihydrofolate reductase (DHFR)-mediated reduction in oxidant stress in endothelial cells and angiotensin II-infused mice: a novel HPLC-based fluorescent assay for DHFR activity. J Mol Cell Cardiol 2009;47:752–60.Google Scholar

  • 87.

    Liu J, Schmitz JC, Lin X, Tai N, Yan W, Farrell M, et al. Thymidylate synthase as a translational regulator of cellular gene expression. Biochim Biophys Acta 2002;1587:174–82.Google Scholar

  • 88.

    Jain M, Nilsson R, Sharma S, Madhusudhan N, Kitami T, Souza AL, et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 2012;336:1040–4.CrossrefGoogle Scholar

  • 89.

    Zhang WC, Shyh-Chang N, Yang H, Rai A, Umashankar S, Ma S, et al. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 2012;148:259–72.CrossrefGoogle Scholar

  • 90.

    Krupenko SA. FDH: an aldehyde dehydrogenase fusion enzyme in folate metabolism. Chem Biol Interact 2009;178:84–93.CrossrefGoogle Scholar

  • 91.

    Oleinik NV, Krupenko NI, Krupenko SA. Epigenetic silencing of ALDH1L1, a metabolic regulator of cellular proliferation, in cancers. Genes Cancer 2011;2:130–9.CrossrefGoogle Scholar

  • 92.

    Oleinik NV, Krupenko NI, Priest DG, Krupenko SA. Cancer cells activate p53 in response to 10-formyltetrahydrofolate dehydrogenase expression. Biochem J 2005;391:503–11.Google Scholar

  • 93.

    Oleinik NV, Krupenko NI, Krupenko SA. Cooperation between JNK1 and JNK2 in activation of p53 apoptotic pathway. Oncogene 2007;26:7222–30.Google Scholar

  • 94.

    Ghose S, Oleinik NV, Krupenko NI, Krupenko SA. 10-formyltetrahydrofolate dehydrogenase-induced c-Jun-NH2-kinase pathways diverge at the c-Jun-NH2-kinase substrate level in cells with different p53 status. Mol Cancer Res 2009;7:99–107.Google Scholar

  • 95.

    Luka Z, Mudd SH, Wagner C. Glycine N-methyltransferase and regulation of S-adenosylmethionine levels. J Biol Chem 2009;284:22507–11.CrossrefGoogle Scholar

  • 96.

    Tseng TL, Shih YP, Huang YC, Wang CK, Chen PH, Chang JG, et al. Genotypic and phenotypic characterization of a putative tumor susceptibility gene, GNMT, in liver cancer. Cancer Res 2003;63:647–54.Google Scholar

  • 97.

    Huang YC, Lee CM, Chen M, Chung MY, Chang YH, Huang WJ, et al. Haplotypes, loss of heterozygosity, and expression levels of glycine N-methyltransferase in prostate cancer. Clin Cancer Res 2007;13:1412–20.CrossrefGoogle Scholar

  • 98.

    Martinez-Chantar ML, Vazquez-Chantada M, Ariz U, Martinez N, Varela M, Luka Z, et al. Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice. Hepatology 2008;47:1191–9.Google Scholar

About the article

Corresponding author: Sergey A. Krupenko, Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425, USA, Phone: +1 843 792–0845


Received: 2012-08-30

Accepted: 2012-11-09

Published Online: 2012-12-12

Published in Print: 2013-03-01


Citation Information: Clinical Chemistry and Laboratory Medicine, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2012-0561.

Export Citation

©2013 by Walter de Gruyter Berlin Boston. Copyright Clearance Center

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Rauf Ahmad Najar, Nissar Ahmad Wani, Javeed Ahmad Bhat, Nawab John Dar, Beenish Rahat, Ajai Prakash Gupta, Jaspreet Kaur, Jyotdeep Kaur, and Abid Hamid
The Journal of Nutritional Biochemistry, 2017
[2]
Mariann Fagernæs Hansen, Sarah Østrup Jensen, Ernst-Martin Füchtbauer, and Pia M Martensen
British Journal of Cancer, 2017, Volume 116, Number 6, Page 752
[3]
Suchandra DebRoy, Inga I. Kramarenko, Sampa Ghose, Natalia V. Oleinik, Sergey A. Krupenko, Natalia I. Krupenko, and Klaus Roemer
PLoS ONE, 2013, Volume 8, Number 7, Page e70062
[4]
Stephen Beesley, James Olcese, Charles Saunders, Ewa A. Bienkiewicz, and Whitney Wharton
Journal of Alzheimer's Disease, 2016, Volume 55, Number 3, Page 1155
[5]
Ayano HIRAKO, Satoshi FURUKAWA, Takashi TAKEUCHI, and Akihiko SUGIYAMA
Journal of Veterinary Medical Science, 2016, Volume 78, Number 2, Page 213
[6]
Bernard J. Brabin, Sabine Gies, Stephen Owens, Yves Claeys, Umberto D’Alessandro, Halidou Tinto, and Loretta Brabin
Trials, 2016, Volume 17, Number 1
[7]
Tseng-Ting Kao, Chia-Yi Chu, Gang-Hui Lee, Tsun-Hsien Hsiao, Nai-Wei Cheng, Nan-Shan Chang, Bing-Hung Chen, and Tzu-Fun Fu
Neurobiology of Disease, 2014, Volume 71, Page 234
[8]
András Jeney
Orvosi Hetilap, 2013, Volume 154, Number 44, Page 1754
[9]
Claudia Kappen
American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2013, Volume 163, Number 4, Page 333

Comments (0)

Please log in or register to comment.
Log in